Rhumbline Advisers Increases Position in Teladoc Health, Inc. (NYSE:TDOC)

Rhumbline Advisers lifted its stake in shares of Teladoc Health, Inc. (NYSE:TDOC - Free Report) by 62.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 276,535 shares of the health services provider's stock after buying an additional 106,770 shares during the period. Rhumbline Advisers owned approximately 0.16% of Teladoc Health worth $2,704,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. ICA Group Wealth Management LLC acquired a new position in Teladoc Health during the fourth quarter valued at $28,000. Principal Securities Inc. acquired a new position in Teladoc Health during the fourth quarter valued at $45,000. Signaturefd LLC lifted its position in Teladoc Health by 148.7% during the second quarter. Signaturefd LLC now owns 2,868 shares of the health services provider's stock valued at $28,000 after purchasing an additional 1,715 shares during the period. International Assets Investment Management LLC acquired a new position in Teladoc Health during the second quarter valued at $29,000. Finally, SageView Advisory Group LLC acquired a new position in Teladoc Health during the first quarter valued at $48,000. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, COO Michael Willem Waters sold 6,053 shares of the company's stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $8.14, for a total transaction of $49,271.42. Following the sale, the chief operating officer now directly owns 74,214 shares of the company's stock, valued at approximately $604,101.96. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Teladoc Health news, COO Michael Willem Waters sold 6,053 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $8.14, for a total value of $49,271.42. Following the sale, the chief operating officer now directly owns 74,214 shares of the company's stock, valued at approximately $604,101.96. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Laizer Kornwasser sold 10,879 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $8.14, for a total transaction of $88,555.06. Following the completion of the sale, the chief executive officer now directly owns 99,929 shares in the company, valued at $813,422.06. The disclosure for this sale can be found here. Insiders have sold a total of 57,819 shares of company stock valued at $442,204 in the last ninety days. Company insiders own 0.95% of the company's stock.

Teladoc Health Trading Up 1.0 %

NYSE:TDOC traded up $0.09 on Thursday, hitting $9.18. The stock had a trading volume of 5,025,841 shares, compared to its average volume of 5,544,047. The company has a quick ratio of 1.62, a current ratio of 1.66 and a debt-to-equity ratio of 0.66. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -6.46 and a beta of 0.90. The company has a fifty day moving average price of $8.05 and a two-hundred day moving average price of $10.97. Teladoc Health, Inc. has a 1-year low of $6.76 and a 1-year high of $22.54.

Teladoc Health (NYSE:TDOC - Get Free Report) last announced its earnings results on Wednesday, July 31st. The health services provider reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.08. Teladoc Health had a negative net margin of 38.54% and a negative return on equity of 10.25%. The firm had revenue of $642.44 million for the quarter, compared to the consensus estimate of $649.34 million. Equities research analysts expect that Teladoc Health, Inc. will post -1.18 earnings per share for the current fiscal year.

Analyst Ratings Changes

TDOC has been the subject of a number of research reports. Needham & Company LLC restated a "hold" rating on shares of Teladoc Health in a research report on Thursday, August 1st. Stifel Nicolaus cut their price objective on shares of Teladoc Health from $16.00 to $9.00 and set a "hold" rating for the company in a report on Thursday, August 1st. DA Davidson cut their target price on shares of Teladoc Health from $12.00 to $8.00 and set a "neutral" rating for the company in a research note on Thursday, August 1st. Deutsche Bank Aktiengesellschaft cut their target price on shares of Teladoc Health from $15.00 to $10.00 and set a "hold" rating for the company in a research note on Friday, August 2nd. Finally, Oppenheimer cut their target price on shares of Teladoc Health from $21.00 to $17.00 and set an "outperform" rating for the company in a research note on Thursday, August 1st. Fifteen equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Teladoc Health has an average rating of "Hold" and a consensus price target of $12.31.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.